Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union
Pharmaceutics · 10.02.2023 · 15 (2) · 601
DOI: 10.3390/pharmaceutics15020601 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 10.02.2023. Verfasst von Alfredo García-Arieta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Área de Farmacocinética y Medicamentos Genéricos, División de Farmacología y Evaluación Clínica, Departamento de Medicamentos de Uso Humano, Agencia …. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.
Abstract (Originalsprache)
The development of second-entry topical products is hampered by several factors. The excipient composition should be similar to the reference product because excipients may also contribute to efficacy. Conventional pharmacokinetic bioequivalence studies were not considered acceptable because drug concentrations are measured downstream after the site of action. There was no agreed methodology to characterize the microstructure of semisolids, and waivers of therapeutic equivalence studies with clinical endpoints were not possible. Only the vasoconstrictor assay for corticosteroids was accepted as a surrogate. This paper describes the implementation of the European Union’s stepwise approach for locally acting products to cutaneous products, discusses the equivalence requirements of the EMA Draft Guideline on the Quality and Equivalence of Topical Products, and compares them with the US Food and Drug Administration recommendations. Step 1 includes the possibility of waivers for simple formulations based on in vitro data only (Q1 + Q2 + Q3 + IVRT). Step 2 includes step 1 requirements plus a kinetic study (TS/IVPT/PKBE) to compare the local availability of complex formulations. Step 3 refers to clinical studies with pharmacodynamic/clinical endpoints. As excipients may affect the local tolerability and efficacy of the products, the similarity of excipient composition is required in all steps, except where clinical endpoints are compared.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Área de Farmacocinética y Medicamentos Genéricos, División de Farmacología y Evaluación Clínica, Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, 28022 Madrid, Spain.
- Division of Biopharmaceutics Evaluation, Bureau of Pharmaceutical Sciences, Pharmaceutical Drugs Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada.
- Norms and Standards for Pharmaceuticals, Health Products Policy and Standards, Access to Medicines and Health Products Division, World Health Organization, 1211 Geneva, Switzerland.
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain.
- Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia-University of Valencia, 46022 Valencia, Spain.
ORCID-Profile: Alfredo García-Arieta, Virginia Merino, Víctor Mangas-Sanjuan
Förderung
- World Health Organization
Zitieren
APA
García-Arieta, A., Gordon, J., Gwaza, L., Merino, V., & Mangas-Sanjuan, V. (2023). Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union. Pharmaceutics, 15(2), 601. https://doi.org/10.3390/pharmaceutics15020601
Vancouver
García-Arieta A, Gordon J, Gwaza L, Merino V, Mangas-Sanjuan V. Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union. Pharmaceutics. 2023;15(2):601. doi:10.3390/pharmaceutics15020601
BibTeX
@article{GarcaArieta2023,
author = {García-Arieta, Alfredo and Gordon, John and Gwaza, Luther and Merino, Virginia and Mangas-Sanjuan, Víctor},
title = {Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {2},
pages = {601},
doi = {10.3390/pharmaceutics15020601}
}
EUVIMED